Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ENTA Enanta Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: ENTA
Price (delayed)
$7.47
Market cap
$159.68M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.54
Enterprise value
$283.58M
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections
Highlights
ENTA's net income is up by 27% year-on-year and by 8% since the previous quarter
The EPS has grown by 27% year-on-year and by 8% since the previous quarter
The equity has decreased by 44% YoY and by 16% from the previous quarter
Enanta Pharmaceuticals's quick ratio has decreased by 24% YoY and by 5% QoQ
Key stats
What are the main financial stats of ENTA
Market
Valuations
Earnings
Shares outstanding
21.38M
Market cap
$159.68M
Enterprise value
$283.58M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.7
Price to sales (P/S)
2.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.4
Revenue
$64.46M
Gross profit
$64.46M
Operating income
-$102.11M
Net income
-$96.42M
EBIT
-$90.28M
EBITDA
-$87.12M
Free cash flow
-$82.24M
Per share
Balance sheet
Liquidity
EPS
-$4.54
EPS diluted
-$4.54
Free cash flow per share
-$3.85
Book value per share
$4.38
Revenue per share
$3.02
TBVPS
$15.12
Total assets
$322.99M
Total liabilities
$229.46M
Debt
$184.11M
Equity
$93.54M
Working capital
$196.91M
Debt to equity
1.97
Current ratio
5.29
Quick ratio
4.36
Net debt/EBITDA
-1.42
Margins
Efficiency
Dividend
EBITDA margin
-135.1%
Gross margin
100%
Net margin
-149.6%
Operating margin
-158.4%
Return on assets
-26.7%
Return on equity
-79.8%
Return on invested capital
-20.4%
Return on capital employed
-32.6%
Return on sales
-140.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ENTA stock price
How has the Enanta Pharmaceuticals stock price performed over time
Intraday
3.61%
1 week
25.97%
1 month
47.92%
1 year
-40.43%
YTD
29.91%
QTD
35.33%
Financial performance
How have Enanta Pharmaceuticals's revenue and profit performed over time
Revenue
$64.46M
Gross profit
$64.46M
Operating income
-$102.11M
Net income
-$96.42M
Gross margin
100%
Net margin
-149.6%
ENTA's net income is up by 27% year-on-year and by 8% since the previous quarter
The company's operating income rose by 25% YoY and by 7% QoQ
The net margin has grown by 17% YoY and by 5% from the previous quarter
The operating margin has grown by 15% YoY and by 4.4% from the previous quarter
Price vs fundamentals
How does ENTA's price correlate with its fundamentals
Growth
What is Enanta Pharmaceuticals's growth rate over time
Valuation
What is Enanta Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.7
P/S
2.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.4
The EPS has grown by 27% year-on-year and by 8% since the previous quarter
The equity has decreased by 44% YoY and by 16% from the previous quarter
ENTA's P/B is 26% below its 5-year quarterly average of 2.3 but 13% above its last 4 quarters average of 1.5
The price to sales (P/S) is 69% lower than the 5-year quarterly average of 8.0 and 9% lower than the last 4 quarters average of 2.7
Enanta Pharmaceuticals's revenue has decreased by 12% YoY and by 3.2% from the previous quarter
Efficiency
How efficient is Enanta Pharmaceuticals business performance
Enanta Pharmaceuticals's return on equity has decreased by 23% YoY and by 6% QoQ
The return on sales has grown by 14% year-on-year and by 3.8% since the previous quarter
ENTA's return on invested capital is up by 14% year-on-year and by 2.4% since the previous quarter
Enanta Pharmaceuticals's ROA has increased by 9% YoY and by 2.2% from the previous quarter
Dividends
What is ENTA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ENTA.
Financial health
How did Enanta Pharmaceuticals financials performed over time
The company's total assets is 41% higher than its total liabilities
Enanta Pharmaceuticals's quick ratio has decreased by 24% YoY and by 5% QoQ
The company's total assets fell by 22% YoY and by 7% QoQ
The debt is 97% more than the equity
The company's debt to equity has surged by 68% YoY and by 18% QoQ
The equity has decreased by 44% YoY and by 16% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.